CureVac sees cash runway into 2028

Cash and cash equivalents amounted to EUR 392.7 million at the end of June 2025, decreasing from EUR 481.7 million at the end of 2024. In the first half of 2025, cash used in operations was mainly allocated to ongoing research and development activities to advance candidates in oncology precision immunotherapies and prophylactic vaccines and to further develop CureVac’s (CVAC) mRNA technology. The cash outflow for the first half of 2025 decreased significantly compared to the first half of 2024 resulting from: the prior year period being impacted by extraordinary payments related to the termination of raw material commitments and the payment of a contract manufacturing organization-related arbitration award for the first-generation COVID-19 vaccine, CVnCoV, and the strategic restructuring initiated in July 2024. CureVac completed the intended workforce reduction as part of the strategic restructuring resulting in decreased personnel expenses, while implementing further cost reductions and increasing cost discipline through the organization. The company reaffirms its expected cash runway into 2028.